In Vivo and Mechanistic Studies on Antitumor Lead 7-Methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-one and Its Modification as a Novel Class of Tubulin-Binding Tumor-Vascular Disrupting Agents-Reference-Cited by-同舟云学术

In Vivo and Mechanistic Studies on Antitumor Lead 7-Methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-one and Its Modification as a Novel Class of Tubulin-Binding Tumor-Vascular Disrupting Agents

Published:2017-06-27 Issue:13 Volume:60 Page:5586-5598
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Cui Mu-Tian¹,Jiang Li¹,Goto Masuo²,Hsu Pei-Ling²,Li Linna³,Zhang Qi³,Wei Lei¹,Yuan Shou-Jun³,Hamel Ernest⁴,Morris-Natschke Susan L.²,Lee Kuo-Hsiung²⁵^ORCID,Xie Lan¹²

Affiliation:

1. Beijing Institute of Pharmacology and Toxicology, 27 Tai-Ping Road, Beijing 100850, China

2. Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States

3. Beijing Institute of Radiation Medicine, 27 Tai-Ping Road, Beijing 100850, China

4. Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick National Laboratory for Cancer Research, National Institutes of Health, Frederick, Maryland 21702, United States

5. Chinese Medicine Research and Development Center, China Medical University and Hospital, Taichung 40402, Taiwan

Funder

National Cancer Institute

National Natural Science Foundation of China

Eshelman Institute for Innovation, University of North Carolina

Department of Health, Taiwan

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b00273